Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

QR Pharma commences clinical trial of Posiphen in early stage AD patients

QR Pharma, Inc. , a developer of novel drugs to treat Alzheimer’s disease, announced today that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.

10 Feb 2010

Huntington's disease: Latrepirdine appears well-tolerated and beneficial

A medication previously studied in patients with Alzheimer's disease (latrepirdine) appears well tolerated and may improve thinking, learning and memory skills among individuals with Huntington's disease, according to a report in the February issue of Archives of Neurology, one of the JAMA/Archives journals.

10 Feb 2010

Neuroimaging technique could help in devising effective treatments for Alzheimer's disease

Scientists have determined that a new instrument known as PIB-PET is effective in detecting deposits of amyloid-beta protein plaques in the brains of living people, and that these deposits are predictive of who will develop Alzheimer's disease.

10 Feb 2010

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

Sequenom, Inc., today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

10 Feb 2010

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Maternal obesity increases offspring's risk of developing inflammation-related disorders

As if there are not enough reasons for obese people to lose weight, a new research report published online in The FASEB Journal (http://www.fasebj.org), adds several more. In a study involving rats, researchers from Duke University found that obesity in mothers causes cellular programming in utero that predisposes offspring to inflammation-related disorders (such as Alzheimer's, Parkinson's, type 2 diabetes, stroke, heart disease, and more) from the day that they are born, regardless of whether or not the offspring are obese themselves.

10 Feb 2010

Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinson’s disease biomarker

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: “Development of an alpha6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson’s Disease Biomarker” and is the second awarded to Targacept by MJFF in the last six months.

9 Feb 2010

Mediterranean diet can avoid brain infarcts, reduce risk of Alzheimer's disease

A Mediterranean diet may help people avoid the small areas of brain damage that can lead to problems with thinking and memory, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

9 Feb 2010

KineMed, Bristol-Myers Squibb broaden collaboration to develop novel mechanisms for Alzheimer’s disease

KineMed, Inc. a translational and personalized medicine development company, today announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) in the area of Alzheimer’s disease and other neurodegenerative conditions.

9 Feb 2010

Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule

Resverlogix Corp. announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic.

9 Feb 2010

High BP may predict dementia in older adults with cognitive impairment

High blood pressure appears to predict the progression to dementia in older adults with impaired executive functions (ability to organize thoughts and make decisions) but not in those with memory dysfunction, according to a report in the February issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Feb 2010

Dimebon drug associated with improved cognitive function in patients with Huntington's disease

An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of Neurology.

9 Feb 2010

Marijuana ineffective against Alzheimer's disease in animal model

The benefits of marijuana in tempering or reversing the effects of Alzheimer's disease have been challenged in a new study by researchers at the University of British Columbia and Vancouver Coastal Health Research Institute.

8 Feb 2010

10 helpful tips to safeguard Alzheimer's patients

An ID bracelet, like the one offered through the Alzheimer's Association's MedicAlert + Safe Return program, helps the police or a Good Samaritan get a missing person back home safely or medical attention.

5 Feb 2010

Project Lifesaver International, Xanboo to offer medical facilities to help people with cognitive disorder

Project Lifesaver International, a non-profit organization specializing in training public safety agencies on search and rescue programs to help individuals with cognitive conditions that wander, announced today they will be teaming with Xanboo, a wireless equipment company that supplies a wide variety of intrusion and security products, including indoor and outdoor cameras, control of lighting, door/window censors, and other security products.

5 Feb 2010

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled "Methods for Reprogramming Somatic Cells." Upon issuance, the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics.

5 Feb 2010

Immigrants may be healthier than long-term residents

New immigrants to North America may be less likely to have a stroke at a young age than long-time residents, according to a study published in the February 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Feb 2010

UCSF studies show relationship between Alzheimer's disease and smoking

A UCSF analysis of published studies on the relationship between Alzheimer's disease and smoking indicates that smoking cigarettes is a significant risk factor for the disease. After controlling for study design, quality of the journals, time of publication, and tobacco industry affiliation of the authors, the UCSF research team also found an association between tobacco industry affiliation and the conclusions of individual studies.

4 Feb 2010

Researchers develop simple urine test to predict and diagnose preeclampsia

Researchers at Yale School of Medicine have developed a simple urine test to rapidly predict and diagnose preeclampsia, a common, but serious hypertensive complication of pregnancy.

4 Feb 2010

Alzheimer's Disease News and Research

Further Reading

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

QR Pharma commences clinical trial of Posiphen in early stage AD patients

Huntington's disease: Latrepirdine appears well-tolerated and beneficial

Neuroimaging technique could help in devising effective treatments for Alzheimer's disease

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Maternal obesity increases offspring's risk of developing inflammation-related disorders

Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinson’s disease biomarker

Mediterranean diet can avoid brain infarcts, reduce risk of Alzheimer's disease

KineMed, Bristol-Myers Squibb broaden collaboration to develop novel mechanisms for Alzheimer’s disease

Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule

High BP may predict dementia in older adults with cognitive impairment

Dimebon drug associated with improved cognitive function in patients with Huntington's disease

Marijuana ineffective against Alzheimer's disease in animal model

10 helpful tips to safeguard Alzheimer's patients

Project Lifesaver International, Xanboo to offer medical facilities to help people with cognitive disorder

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Immigrants may be healthier than long-term residents

UCSF studies show relationship between Alzheimer's disease and smoking

Researchers develop simple urine test to predict and diagnose preeclampsia

Aneuro: A Year of Neuroscience in Review eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News